NCT03681275View on ClinicalTrials.gov

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
Diaphragm Injury
Interventions
DRUG

Tofacitinib 10 MG [Xeljanz]

administered twice daily for two days

DRUG

Placebo to match Tofacitinib

administered twice daily for two days

Trial Locations (1)

94305

RECRUITING

Stanford University Medical Center, Stanford

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Stanford University

OTHER